Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines

6 Dec 2022

Abstract excerpt

The SARS-CoV-2 omicron variant XBB sublineage, a BA.2.10.1–BA.2.75 recombinant classified as variant under monitoring by WHO, has been found in 35 countries,1WHOCOVID-19 weekly epidemiological update - 26 October 2022.https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---26-october-2022Date: 2022Date accessed: October 30, 2022Google Scholar and has become the dominant strain in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36493789
DOI: 10.1016/s2666-5247(22)00335-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccinesPMID 36493789Read ↗

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sublineages in the face of maturing antibody breadth at the population levelSemantic proximity Read ↗

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population levelSemantic proximity Read ↗

Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022Semantic proximity Read ↗

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1Semantic proximity Read ↗

Emergence and Antibody Evasion of BQ and BA.2.75 SARS-CoV-2 Sublineages in the Face of Maturing Antibody Breadth at the Population LevelSemantic proximity Read ↗

SARS-CoV-2 Omicron BA.2.86: less neutralization evasion compared to XBB sub-variantsSemantic proximity Read ↗

XBB .1.5 neutralizing antibodies upon bivalent COVID ‐19 vaccination are similar to XBB but lower than BQ .1.1Semantic proximity Read ↗

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasionSemantic proximity Read ↗

Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 variantSemantic proximity Read ↗

Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trialSemantic proximity Read ↗

Continued evasion of neutralizing antibody response by Omicron XBB.1.16Semantic proximity Read ↗

Breakthrough infection with Omicron subvariant BF.7 induces broadly neutralizing antibodies to SARS-CoV-2 variants including XBB lineageSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.